Table 4.
Efficacy results
| Outcome | Level 1 (n = 6) | Level 2 (n = 12) | Total (n = 18) | |||
|---|---|---|---|---|---|---|
| n (%) | 95% CI (%) | n (%) | 95% CI (%) | n (%) | 95% CI (%) | |
| Complete response (CR) | 0 | – | 0 | – | 0 | – |
| Partial response (PR) | 2 (33.3) | – | 3 (25.0) | – | 5 (27.8) | – |
| Stable disease (SD) | 2 (33.3) | – | 6 (50.0) | – | 8 (44.4) | – |
| Progressive disease | 1 (16.7) | – | 2 (16.7) | – | 3 (16.7) | – |
| Not evaluable | 1 (16.7) | – | 1 (8.3) | – | 2 (11.1) | – |
| Overall response rate (CR + PR) | 2 (33.3) | 4.3–77.7 | 3 (25.0) | 5.5–57.2 | 5 (27.8) | 9.7–53.5 |
| Disease control rate (CR + PR + SD) | 4 (66.7) | 22.3–95.7 | 9 (75.0) | 42.8–94.5 | 13 (72.2) | 46.5–90.3 |
CI confidence interval